Trial Profile
A Randomized, Active-Controlled, Open-Label, Phase 2 Clinical Trial of BMS-986213, in Combination With Various Standard-of-Care Therapeutic Regimens, in Participants With Recurrent, Locally Advanced, or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction (GEJ) Adenocarcinoma
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 20 May 2020
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Nivolumab/relatlimab (Primary) ; Paclitaxel (Primary) ; Ramucirumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 17 May 2020 Planned End Date changed from 11 Jul 2023 to 30 Sep 2024.
- 17 May 2020 Planned primary completion date changed from 3 Jan 2021 to 27 Feb 2022.
- 17 May 2020 Planned initiation date changed from 15 Jun 2019 to 31 Oct 2019.